Hopt U T
Klinik für Allgemein-und Viszeralchirurgie, Chirurgische Universitätsklinik Freiburg.
Zentralbl Chir. 2006 Apr;131(2):115-20. doi: 10.1055/s-2006-921535.
For patients with carcinoma in the head of the pancreas surgical resection remains the only chance of cure. Perioperative mortality could be reduced in the last years dramatically, postoperative morbidity, however, remains high. Only a small percentage of all patients suffering from pancreas carcinoma are good candidates for an operative therapy. The most frequent contraindications are metastases in the liver or the peritoneum or a locally too advanced tumor. The extent of surgical resection necessary in patients with pancreas carcinoma is still in discussion. Even after an operation under curative aspects long term results remain disappointing. Median survival still ranges only about 16 months. A substantial improvement of long term- survival can only be expected from new multimodal therapeutic strategies. Adjuvant chemotherapy should strongly be recommended after resection of a pancreas carcinoma. Neoadjuvant therapy on the other hand is still an experimental procedure and under evaluation in ongoing prospective randomized studies.
对于胰头癌患者,手术切除仍是唯一的治愈机会。在过去几年中,围手术期死亡率已大幅降低,但术后发病率仍然很高。在所有胰腺癌患者中,只有一小部分适合进行手术治疗。最常见的禁忌症是肝脏或腹膜转移或局部肿瘤进展过快。胰腺癌患者所需的手术切除范围仍在讨论中。即使在根治性手术后,长期结果仍然令人失望。中位生存期仍仅约为16个月。只有通过新的多模式治疗策略才能大幅提高长期生存率。强烈建议在胰腺癌切除术后进行辅助化疗。另一方面,新辅助治疗仍然是一种实验性程序,正在进行的前瞻性随机研究中进行评估。